Table 1
COVID-19 vaccination timing for patients with cancer in need of therapy
| Therapy | Timing |
| Non-cytotoxic monoclonal antibody inhibitors | No specific timing consideration |
| Non-cytotoxic immunotherapy chemotherapy | |
| Chemotherapytyrosine kinase inhibitors | |
| Poly-ADP-ribose polymerase (PARP) | |
| Hormone treatments | |
| Radiation therapy | |
| Targeted therapy | |
| Immune checkpoint inhibitors (ICI) alone | |
| A combination of ICI and chemotherapy | One to three weeks before the treatments |
| Surgical treatment | |
| Elective surgery | Two weeks prior |
| Emergency surgery | Four weeks after |
| Haematopoietic stem cell transplantation (allogenic or autologous) | Three to six months after |
| CAR-T cell therapy or bone marrow | Three to six months after |
| Anti-CD20 antibody therapy | Six months after |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.